Serum levels of tumor maker CA 19-9 were quantified in healthy young and middle adults, including both genders. Participants had to have no sign of tumor or inflammatory diseases. Technically, level of CA 19-9 as quantifying by IRMA kid of CISbio International was reliable with%CV ranged from 0.1 to 5.4. Average value of CA 19-9 is 17.11+/-11.06. Level in high area was no more than 35.7 U/mL. Upper and lower marginal areas were 26.61 U/mL and 5.68 U/mL, respectively. There was no significant difference between two genders
Immunoradiometric Assay ; Serum

The human thyroglobulin (hTG) level was quantified in 31 serum samples taken from healthy people who aged from 18-55 years old. The standard curve, accuracy of technique and the serum hTG level of healthy people was determined. The results showed that the hTG quantified technique using immunoradiometric assay (IRMA) kits of CIS Bio International provided high accuracy. The average serum hTG level of healthy people is 7.35+/-6.99ng/ml; with common rage is 0.00 to 2ng/ml.
Thyroglobulin ; Immunoradiometric Assay

The serum concentrations of tumor markers of hTG and hCT in 33 healthy people were determined by the immunoradiometry assay (IRMA) has shown that the concentration of hTG and hCT was 7.35 +/- 6.99 mg/ml 5.74 +/-5.92ng/ml, respectively. There was no difference of concentrations of hCT and hTG between men and women.
Thyroid Neoplasms ; Immunoradiometric Assay

We measured serum levels of CA-125 and Tissue polypeptide antigen(TPA) in 135 patients with pelvic tumors(129 benign pelvic tumors and 6 malignant ovarian tumors) preoperatively. Each tumor marker was measured by immunoradiometric assay. Serum CA-125 levels of 35.0U/ml, 65.0U/ml and TPA levels of 80.0U/ml, 100.0U/ml were determined as cut-off values. The results were evaluated by each tumor marker and two tumor markers coincidently. The results were as follows : (continue)
Humans ; Immunoradiometric Assay ; Biomarkers, Tumor

The quantification of CA 72-4 and CA 19-9 in normal people and patients with the peptic cancer was analysed and evalutated in the clinical application. The conentration of CA 72-4 and 19-9 in the normal people (disease free, tumor and infection free) and patients with the pepsic cancer (diagnosed by pathological anatomy and cytology) were quantified an compared.
Immunoradiometric Assay ; Peptic Ulcer ; neoplasms

OBJECTIVE: The purpose of this study is to evaluate the clinical usefulness of serum level of CA125 and CA19-9 to assess the severity of endometriosis. METHODS: The study was conducted on 80 patients with histologically diagnosed endometriosis and 20 patients in control group. Preoperative serum CA125 and CA19-9 levels were measured by immunoradiometric assay and the severity of disease was staged according to the revised American Fertility Society (1985) classification system. RESULTS: Both serum level of CA125 and CA19-9 in endometriosis patient (81.7+/-120.44 U/mL, 47.1+/-80.74 U/mL, Mean+/-SD) were higher than control group (10.8+/-6.48 U/mL, 11.7+/-8.82 U/mL, Mean+/-SD)(p=0.001, p=0.054). The serum CA125 level increased significantly according to stages (p=0.051), but serum CA19-9 level showed an increasing trend (p>0.05). With the cutoff value of CA125 with 35 U/mL and CA19-9 with 37 U/mL, overall positive rate for CA125, CA19-9, and CA125 combined with CA19-9 was 45.1%, 33.8%, and 52.5%. There was no difference between the positive rate with CA125 combined with CA19-9 (52.5%) and that with CA125 alone (45.1%)(p>0.05). With the cutoff value of CA125 with 15 U/mL and CA19-9 with 9 U/mL, overall positive rate for CA125, CA19-9, and CA125 combined with CA19-9 was 82.5%, 76.3%, and 92.5%, the positive rate with CA125 combined with CA19-9 (92.5%) was higher than that with CA125 alone (82.5%)(p=0.056). CONCLUSION: Because the positive rate with combined serum CA125 and CA19-9 level is not higher than that with serum CA125 alone for the severity assessment of endometriosis, it is recommended to use serum CA125 level alone.
Classification ; Endometriosis* ; Female ; Fertility ; Humans ; Immunoradiometric Assay

BACKGROUND: Serum thyroglobulin(Tg) is a valuable and sensitive tool needed in the follow-up of patients with differentiated thyroid cancer(DTC), but antithyroglobulin antibody(Anti-Tg), common in patients with DTC, can interfere with the assay for Tg. In this study, we evaluated the influence of Anti-Tg on the measurement of Tg using the immunoradiometric assay(IRMA). METHODS: In using ELSA-hTg in vivo test(CIS international, Schering, France), a solid phase two-site IRMA was used to measure Tg(23.5ng/mL, 62.5ng/mL) under the absence or presence of three concentrations of Anti-Tg(25U/mL, 50U/mL, 100U/mL). We also performed Tg measurement using patients serum that was mixed with patients serum containing high Anti-Tg. ANOVA and Scheffe tests were performed to evaluate the effect of Anti-Tg on Tg IRMA, and an inverse regression was made to calculate the level of Tg from measured Tg and used Anti-Tg levels and also to assess the degree of effect of anti-Tg on Tg IRMA. RESULTS: In measuring Tg using the standard solution, the presence of Anti-Tg resulted in a falsely suppressed Tg value. The IRMAs for 23.5ng/mL of the standard Tg solution resulted in 24.5+/-.1 ng/mL under no Anti-Tg, 11.8+/-.4ng/mL under 25U/mL of Anti-Tg, 7.7+/-.1ng/mL under 50U/mL of Anti-Tg, and 4.5+/-.4ng/mL under 100U/mL of Anti-Tg. IRMAs 62.5ng/mL of the standard Tg solution resulted in 65.9+/-.7ng/mL under no Anti-Tg, 36.3+/-.2ng/mL under 25U/mL of Anti-Tg, 23.7+/-.7ng/mL under 50U/mL of Anti-Tg, and 14.0+/-.0ng/mL under 100U/mL of Anti-Tg. (ANOVA test, p=0.000). The degree of suppression of the measured Tg value was positively correlated with the Anti-Tg level (Quadratic model regression, Sig T=0.000). The presence of Anti-Tg also resulted in a falsely suppressed Tg value for the Tg measurement using patient's serum. CONCLUSION: The presence of Anti-Tg could consist of the use of Tg as a tumor, therefore Anti-Tg should be measured in all patients diagnosed with DTC. The interpretation of the Tg level must be performed with extreme caution in patients with Anti-Tg.
Humans ; Immunoradiometric Assay* ; Thyroglobulin* ; Thyroid Gland

A study was carried out to apply the IRMA to quantity the CA15-3 in the normal person and CA15-3 and CEA in the patients with the breast cancer. The clinical efficacy of CA15-3 and CEA were also evaluated. The subjects were normal people without tumor, chronic diseases, infection, inflamatory, hepatic diseases and the patients with the breast cancer who received the pathological anatomy and cytology.
Breast Neoplasms ; diagnosis ; Immunoradiometric Assay ; neoplasms ; breast

Subjects: Normal people without the benign or malignant tumor; standard sample of CA72-4 with concentrations: 0,3; 25; 50 100 u/ml. The results have shown that the standard chart has relatively same as theory; the change factor CV had value within allowed limit in the range of low concentration of CA 72-4 was 4,05+/- 3,06U/ml. The medium value was 4,92 u/ml. The normal range is from 0 to 9 u/ml. There is insignificant different between women and men.
Neoplasms ; Immunoradiometric Assay ; Tumor Markers, Biological

Participants were 28 healthy people involved in genders, included smokers and non-smokers with age ranged from 18 to 50 years. Standard curve was established using 6 prepared sample kits of manufacturer with levels of 0, 4, 20, 80, 140 and 200ng/ml. The findings suggested that for technical standard, CEA quantification with IRMA using kits of France-based CIS Bio International was reliable, quality of kits and qualification skill is good. Average level of CEA maker in 28 subjects above is 4.19+/-2.35ng/ml with mean-point of 4.48, ranged from 0.00 to 8.37ng/ml. The most common level is 6.37ng/ml. Upper-marginal level is 2.59ng/ml and under-marginal level is 3.36ng/ml. There was insignificant difference between male and female.
Administrative Personnel ; Carcinoembryonic Antigen ; Immunoradiometric Assay ; neoplasms